Delivery Order SPE2DB24D2205-SPE2DB25FECYJ
Award Date
5/29/25
Potential Completion Date
5/30/25
Potential Value
$3.3K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $29,021.99 and a period of performance through April 28, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price, non-set-aside contract with a ceiling value of $1,854.50 and a period of performance through April 16, 2025. AmerisourceBergen Drug Corp holds a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $23,114.91 delivery order contract is for the supply of 40mg Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price delivery order without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,148.38, is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 17, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $2,593.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,568,090,280 units of Vyvanse 70 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with a performance period ending on May 1, 2025. AmerisourceBergen Drug Corp...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 50 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The delivery order has a ceiling value of $1,310.89 and a performance period ending on May 23, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,739.63 firm fixed-price contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set aside and has an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of 40 mg Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed price award with a ceiling value of $2,675.98 and a period of performance through June 5, 2025. The contract is not set-aside and is therefore open to competition. AmerisourceBergen Drug...
This federal contract award, valued at $4,401.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 18, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...